The relevance of chymase in cardiovascular disease is being tested in clinical trials by evaluating the effects of the chymase inhibitor BAY1142524 in patients with post‐myocardial infarction left‐ventricular dysfunction (CHIARA MIA 1, CHIARA MIA 2). Here, CMA1 is linked to cardiovascular disorder.